Vorinostat and Rituximab in Treating Patients With Indolent Non-Hodgkin Lymphoma
Status:
Completed
Trial end date:
2017-06-08
Target enrollment:
Participant gender:
Summary
RATIONALE: Vorinostat may stop the growth of cancer cells by blocking some of the enzymes
needed for cell growth. Monoclonal antibodies, such as rituximab, can block cancer growth in
different ways. Some block the ability of cancer cells to grow and spread. Others find cancer
cells and help kill them or carry cancer-killing substances to them. Giving vorinostat
together with rituximab may kill more cancer cells.
PURPOSE: This phase II trial is studying the side effects of giving vorinostat together with
rituximab and to see how well it works in treating patients with indolent non-Hodgkin
lymphoma.
Phase:
Phase 2
Details
Lead Sponsor:
City of Hope Medical Center
Collaborators:
Merck Sharp & Dohme Corp. National Cancer Institute (NCI)